Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
CD19 chimeric antigen receptor T (CAR-T) cell therapies may have the potential to treat rheumatic diseases in which current therapeutic options are limited, such as lupus, interstitial lung disease and systemic sclerosis.
Research has identified and described a pro-inflammatory cytokine network shared by four rheumatic conditions that may be particularly active in patients with severe disease.
Since starting the ACR on Air podcast in 2019, Mohammad Ursani, MD, FACP, RhMSUS, has become chair of the Committee on Communications and Marketing. Here, he shares some plans for the ACR website, podcast and more.
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.
In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.
The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.